Astellas has announced the in-licensing of a vaccine for respiratory syncytial virus (RSV) from Mymetics Corp. Astellas will pay Mymetics upfront and milestone payments of up to USD 82 million depending on the outcomes of that trial, as well as double-digit royalties on future sales. Astellas retains rights to acquire RSVC and carry out further development and commercialisation activities in the future.